Friday, September 4

Browsing: CAPItello291

Diagnosis

How Do Final CAPItello-291 OS Data Shape Capivasertib Use in Breast Cancer?

By NewsCancerSeptember 4, 20260

In a recent CancerNetwork® Between the Lines program, a panel of breast oncology experts read between the lines of the…

Treatments

CAPItello-291 Study Design and Intermittent Capivasertib Dosing

By NewsCancerSeptember 2, 20260

Erica L. Mayer, MD, MPH, of Dana-Farber Cancer Institute, reviews the design of CAPItello-291, a phase 3, double-blind, placebo-controlled trial…

Diagnosis

Primary Progression-Free Survival Results From CAPItello-291

By NewsCancerSeptember 2, 20260

Erica L. Mayer, MD, MPH, of Dana-Farber Cancer Institute, recaps the primary analysis of CAPItello-291 in hormone receptor positive, human…

Support

Statistical Design of the CAPItello-291 Final Survival Analysis

By NewsCancerSeptember 2, 20260

Erica L. Mayer, MD, MPH, of Dana-Farber Cancer Institute, explains the statistical framework behind the final overall survival analysis of…

► Necessary Cookies Always Active

Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.

► Functional Cookies Remark

Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.

► Analytical Cookies Remark

Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.

► Advertisement Cookies Remark

Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.